Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Total Current Liabilities (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed Total Current Liabilities for 16 consecutive years, with $237.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 59.94% year-over-year to $237.8 million, compared with a TTM value of $237.8 million through Dec 2025, up 59.94%, and an annual FY2025 reading of $237.8 million, up 59.94% over the prior year.
  • Total Current Liabilities was $237.8 million for Q4 2025 at Amicus Therapeutics, up from $198.9 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $237.8 million in Q4 2025 and bottomed at $99.7 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $154.3 million, with a median of $155.5 million recorded in 2024.
  • The sharpest move saw Total Current Liabilities decreased 11.32% in 2024, then skyrocketed 59.94% in 2025.
  • Year by year, Total Current Liabilities stood at $146.0 million in 2021, then dropped by 4.77% to $139.0 million in 2022, then rose by 20.62% to $167.7 million in 2023, then decreased by 11.32% to $148.7 million in 2024, then surged by 59.94% to $237.8 million in 2025.
  • Business Quant data shows Total Current Liabilities for FOLD at $237.8 million in Q4 2025, $198.9 million in Q3 2025, and $167.6 million in Q2 2025.